Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
- PMID: 37783639
- DOI: 10.1016/j.clml.2023.09.004
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Abstract
Black and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivity of clinical trials were discussed, including broadening inclusion/exclusion criteria, reducing the financial and other burdens of trial participants, selecting diverse study sites, including implicit bias training, and taking steps to empower patients.
Keywords: Clinical trial; Diversity; Equity; Inclusivity; Multiple myeloma.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Monique Hartley-Brown: Advisory board participation for Abbvie, BMS, Celgene, GSK, Janssen, Karyopharm, Sanofi. Research funding from BMS /Celgene, GSK, Sanofi. Craig E. Cole: Discussion Board/consultation for Pfizer, Sanofi, Asta-Zenca, Abbvie, Genentech. Research: GSK. Pamela Price: None to report. Michael Andreini: Employee of MMRF. George Mulligan: Employee of MMRF. Anne Quinn Young: Employee of MMRF. Hearn Jay Cho: Employee of MMRF. Research support from Takeda, BMS/Celgene.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical